EVAX Q4 2025 Earnings — Evaxion Biotech A/S Revenue & Financial Results | Market Cap Arena

EVAXEvaxion Biotech A/S

$20M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22,040-81.9% YoY

Gross Profit

-$8M-34160.6% margin

Operating Income

-$4M-18494.8% margin

Net Income

-$6M-26940.1% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

-99.7%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$28M

Total Liabilities

$11M

Stockholders' Equity

$17M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22,040	$122,000	-81.9%
Gross Profit	-$8M	$122,000	-6271.3%
Operating Income	-$4M	-$4M	-1.3%
Net Income	-$6M	-$4M	-63.6%